Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter H.J. Slootbeek"'
Autor:
Clemens Kratochwil, Inge M. van Oort, James Nagarajah, Marcel J.R. Janssen, Samer Ezziddin, Winald R. Gerritsen, Peter H.J. Slootbeek, Maarten J. van der Doelen, Bart de Keizer, Bastiaan M. Privé, Alfred Morgenstern, Ludwike W. M. van Kalmthout, J. Alfred Witjes, Frank Bruchertseifer, Niven Mehra, Martin Gotthardt, Marjolijn J. L. Ligtenberg, Babette I. Laarhuis, Samhita Pamidimarri Naga, Sandra Heskamp
Publikováno v:
Prostate Cancer and Prostatic Diseases, 25, 1, pp. 71-78
Prostate Cancer and Prostatic Diseases, 25, 71-78
Prostate Cancer and Prostatic Diseases, 25, 71-78
Item does not contain fulltext PURPOSE: Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) is a novel treatment for castration-resistant prostate cancer (mCRPC). While the majority of patients responds to PSMA-RLT, with 10-15% having a
Autor:
Sjoerd van Helvert, Niven Mehra, Samhita Pamidimarri Naga, Maren Bormann, Inge M. van Oort, Leonie I. Kroeze, Emmanuel S. Antonarakis, Peter H.J. Slootbeek, Winald R. Gerritsen, Maarten J. van der Doelen, Pedro Isaacsson Velho
Publikováno v:
European Journal of Cancer, 136, 16-24
European Journal of Cancer, 136, pp. 16-24
European Journal of Cancer, 136, pp. 16-24
Purpose Radium-223 is a targeted alpha radiation therapy for metastatic castration-resistant prostate cancer. DNA damage repair (DDR) defective prostate cancers, specifically genetic aberrations leading to homologous recombination deficiency (HRD), a
Autor:
Winald R. Gerritsen, Monika G. Looijen-Salamon, Inge M. van Oort, Leonie I. Kroeze, Uwe Haberkorn, Frank Bruchertseifer, Clemens Kratochwil, José A. E. Custers, Niven Mehra, Peter H.J. Slootbeek, Maarten J. van der Doelen, Alfred Morgenstern, Marcel J.R. Janssen, James Nagarajah
Publikováno v:
Urologic Oncology-Seminars and Original Investigations, 39, 10, pp. 729.e7-729.e16
Urologic Oncology-Seminars and Original Investigations, 39, 729.e7-729.e16
Urologic Oncology-Seminars and Original Investigations, 39, 729.e7-729.e16
Contains fulltext : 237645.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Targeted alpha-radiation therapy (TAT) with (225)Ac-labeled prostate-specific membrane antigen (PSMA) ligands is a promising novel treatment option for metastatic cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9eacf94286e8dbf9d81c066c59b25af
https://doi.org/10.1016/j.urolonc.2020.12.002
https://doi.org/10.1016/j.urolonc.2020.12.002
Publikováno v:
European Journal of Cancer, 144, pp. 395-396
European Journal of Cancer, 144, 395-396
European Journal of Cancer, 144, 395-396
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1206052b7ef7f246ce499433fca1dc4e
https://hdl.handle.net/2066/229525
https://hdl.handle.net/2066/229525
Autor:
Iris S. H. Kloots, Peter H.J. Slootbeek, Minke Smits, Sjoerd van Helvert, Leonie I. Kroeze, Marleen Kets, Katrien Grünberg, Jolique van Ipenburg, Marjolijn Ligtenberg, Jack A. Schalken, Inge M. van Oort, Haiko Bloemendal, Winald R. Gerritsen, Niven Mehra
Publikováno v:
Journal of Clinical Oncology. 40:40-40
40 Background: Castration-resistant prostate cancer (CRPC) comprises distinct molecular actionable subtypes. Radboudumc, a tertiary referral center for PCa, hosts a Molecular Tumor Board (MTB), and frequently sees CRPC patients (pts) for referral for
Autor:
Samhita Pamidimarri Naga, Inge M. van Oort, Marleen L Duizer, Winald R. Gerritsen, Leonie I. Kroeze, Haiko J. Bloemendal, Malou C.P. Kuppen, Niven Mehra, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Carin A. Uyl-de Groot, Hans M. Westgeest, Iris S.H. Kloots, Peter H.J. Slootbeek, Maarten J. van der Doelen
Publikováno v:
International Journal of Cancer, 148(2), 385-395. Wiley-Liss Inc.
International Journal of Cancer, 148, 385-395
International Journal of Cancer, 148, 2, pp. 385-395
International Journal of Cancer
International Journal of Cancer, 148, 385-395
International Journal of Cancer, 148, 2, pp. 385-395
International Journal of Cancer
Platinum‐based chemotherapy is not standard of care for unselected or genetically selected metastatic castration‐resistant prostate cancer (mCRPC) patients. A retrospective assessment of 71 patients was performed on platinum use in the Netherland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79c4ae93d35fe9784f95113f76a3af3
https://pure.eur.nl/en/publications/73fcb740-8fb5-4724-a40b-bf1b43f68133
https://pure.eur.nl/en/publications/73fcb740-8fb5-4724-a40b-bf1b43f68133
Autor:
N. P. van Erp, Harm Westdorp, Linda G W Kerkmeijer, J.A. Schalken, Robert Jan Smeenk, M.H. den Brok, Peter H.J. Slootbeek, J. De Vries, Gosse J. Adema, Mascha Binder, Haiko J. Bloemendal, Niven Mehra, Iris S.H. Kloots, Wim B.M. Gerritsen
Publikováno v:
Annals of Oncology. 32:S671
Autor:
Inge M. van Oort, Leonie I. Kroeze, Maren Bormann, Peter H.J. Slootbeek, Maarten J. van der Doelen, Samhita Pamidimarri Naga, Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Sjoerd van Helvert, Niven Mehra, Winald R. Gerritsen
Publikováno v:
Journal of Clinical Oncology. 38:121-121
121 Background: Ra223 is a therapeutic option for mCRPC patients (pts) with symptomatic bone metastases. DDR-defective prostate cancers, specifically those with homologous recombination deficiency (HRD), accumulate irreparable DNA damage following ge